Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE: Rituximab for Autoimmune Premature Ovarian Insufficiency
NCT07509840Phase 3Recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in premature ovarian insufficiency (POI). Started Feb 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT07509840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509840.